NovaBridge 的 Visara 将眼药 VIS-101 授权给珠穆朗玛峰，用于大中华区和亚洲，预付款为 $7M，里程碑高达 $89M。 NovaBridge’s Visara licenses eye drug VIS-101 to Everest for Greater China and Asia, with $7M upfront and up to $89M in milestones.

NovaBridge生物科学的子公司Visara已为其实验药物VIS-101颁发许可证,专用于大中国、新加坡、韩国和东南亚部分地区用于发展、制造和商业化的珠穆朗玛峰药物。 NovaBridge Biosciences’ subsidiary Visara has licensed its experimental drug VIS-101 exclusively to Everest Medicines for development, manufacturing, and commercialization in Greater China, Singapore, South Korea, and parts of Southeast Asia. 针对VEGF-A和ANG-2的双功能生物药物VIS-101正在中国进行第二阶段试验,用于治疗湿性与年龄相关的黄斑退化,糖尿病黄斑胀和视网膜静脉封闭,预计第三阶段将在2026年完成. VIS-101, a bifunctional biologic targeting VEGF-A and ANG-2, is in a Phase 2 trial in China for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, with Phase 3 expected by 2026. 这笔交易包括预付700万美元,可能达到的里程碑达8 900万美元,以及特许使用费。 The deal includes an upfront payment of $7 million, potential milestones of up to $89 million, and royalties. 珠穆朗玛峰将承担许可证规定的所有支付义务,并偿还Visara以前的费用。 Everest will assume all payment obligations under the license and reimburse Visara for prior costs. 珠穆朗玛峰总裁兼首席财务官伊恩·伍(Ian Woo)加入了NovaBridge的董事会。 Ian Woo, Everest’s President and CFO, has joined NovaBridge’s Board. 合作的目的是加速获得可能改善的治疗,以治疗本区域大量需求未得到满足的严重眼部病症。 The collaboration aims to accelerate access to a potentially improved treatment for serious eye conditions with significant unmet need in the region.